|
|
(PQD3) The role and therapeutic potential of ZNF304 in Ovarian Cancer
|
1R21CA180145-01
|
$208,800
|
$104,400
|
Ozpolat, Bulent
|
UT MD ANDERSON CANCER CTR
|
|
|
A NOVEL MICROFLUIDIC DEVICE FOR SELECTION AND OPTIMIZATION OF DRUG DELIVERY VEHIC
|
5R44CA139841-03
|
$619,304
|
$154,826
|
PRABHAKARPANDIAN, BALABHASKAR
|
CFD RESEARCH CORPORATION
|
|
|
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer
|
5R01CA168900-02
|
$312,080
|
$312,080
|
Powell, Daniel
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Aberrant activation of HGF/MET signaling as a therapeutic target in AML
|
7K08CA160660-03
|
$156,330
|
$78,165
|
Kentsis, Alex
|
SLOAN-KETTERING INST CAN RES
|
|
|
ACE engineered MSCs as a multidrug-delivery platform for breast cancer therapy
|
1R15CA173701-01
|
$452,254
|
$226,127
|
Perkins, Edward
|
MERCER UNIVERSITY MACON
|
|
|
ADAM 17 and glioma-tumor progression and treatment
|
5R01CA129446-05
|
$274,338
|
$90,532
|
JIANG, FENG
|
HENRY FORD HEALTH SYSTEM
|
|
|
Addressing Undruggable Targets Using Oligonucleotides and Small Molecules (PQ18)
|
5R21CA170332-02
|
$155,382
|
$77,691
|
JULIANO, RUDOLPH
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
Adenovirus-host interactions and in vivo virus targeting
|
5R01CA141439-05
|
$373,905
|
$373,905
|
Shayakhmetov, Dmitry
|
UNIVERSITY OF WASHINGTON
|
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIA BC 010984
|
$1,602,394
|
$640,958
|
Rosenberg, Steven
|
CCR (NCI)
|
|
|
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
|
5R01CA138738-05
|
$358,720
|
$358,720
|
Brentjens, Renier
|
SLOAN-KETTERING INST CAN RES
|
|
|
Adoptive transfer of gene-modified autologous T-cells post-ASCT for myeloma
|
5R01CA166961-02
|
$305,741
|
$305,741
|
RAPOPORT, AARON
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
|
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011415
|
$60,238
|
$60,238
|
Kochenderfer, James
|
CCR (NCI)
|
|
|
An Integrated Nano-Cell Delivery Platform of Theranostics for Lung Cancers
|
5R01CA152005-04
|
$193,703
|
$193,703
|
Mohapatra, Shyam
|
UNIVERSITY OF SOUTH FLORIDA
|
|
|
Anti-Cancer RNA Nanoconjugates
|
2R15CA139390-02
|
$398,649
|
$398,649
|
DELONG, ROBERT
|
MISSOURI STATE UNIVERSITY
|
|
|
Anti-pancreatic tumorigenesis by inactivation of SAG/RBX2 E3 ubiquitin ligase
|
1R21CA170995-01A1
|
$202,928
|
$50,732
|
SUN, YI
|
UNIVERSITY OF MICHIGAN
|
|
|
Antibody directed delivery of short interfering RNA for the treatment of ovarian
|
5K08CA163603-02
|
$170,631
|
$170,631
|
PALANCA-WESSELS, MARIA
|
FRED HUTCHINSON CAN RES CTR
|
|
|
Antibody-mediated Gene Therapy for the Treatment of Cancer
|
5K01CA138559-05
|
$142,677
|
$71,339
|
Daniels, Tracy
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
Aptamer targeting of osteopontin in hepatocellular cancer
|
5R21CA155306-02
|
$152,826
|
$152,826
|
KUO, PAUL
|
LOYOLA UNIVERSITY CHICAGO
|
|
|
Aptamer-siRNA Chimeras Targeting HER2-Positive Breast Cancers
|
5R01CA138503-05
|
$295,875
|
$295,875
|
Giangrande, Paloma
|
UNIVERSITY OF IOWA
|
|
|
Aspects of MUC13 Mucin in Cancer
|
5R01CA142736-04
|
|
$0
|
Chauhan, Subhash
|
SANFORD RESEARCH/USD
|
|
|
Aspects of MUC13 Mucin in Cancer
|
7R01CA142736-05
|
$295,230
|
$147,615
|
Chauhan, Subhash
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
|
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
|
5K08CA163941-02
|
$173,772
|
$86,886
|
Moon, Edmund
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011413
|
$30,119
|
$30,119
|
Kochenderfer, James
|
CCR (NCI)
|
|
|
Basis for Lymphomagenesis in Akt2 Transgenic Mice
|
7R01CA077429-14
|
$374,544
|
$93,636
|
Testa, Joseph
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
|
Cancer Center Training - Experimental Therapy Models
|
5T32CA009363-30
|
$240,682
|
$36,102
|
LAND, HARTMUT
|
UNIVERSITY OF ROCHESTER
|
|
|
Cancer Prevention and Treatment by Activation of a Brain-Adipocyte Axis
|
1R01CA166590-01A1
|
$317,475
|
$158,738
|
Cao, Lei
|
OHIO STATE UNIVERSITY
|
|
|
Career Development in Pediatric and Medical Oncology
|
5K12CA076930-15
|
$596,700
|
$119,340
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CAN RES CTR
|
|
|
Carolina Center of Cancer Nanotechnology Excellence
|
5U54CA151652-04
|
$2,058,365
|
$226,420
|
DeSimone, Joseph
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
Cath B and uPAR si RNA constructs regressed glioma growth
|
5R01CA116708-09
|
$310,632
|
$310,632
|
O'BRYAN, JOHN
|
UNIVERSITY OF ILLINOIS
|
|
|
Cell Prep Core
|
ZIC BC 010905
|
$697,120
|
$348,560
|
Wunderlich, John
|
CCR (NCI)
|
|
|
Cell Production Facility Core
|
ZIC BC 011020
|
$697,119
|
$348,559
|
Dudley, Mark
|
CCR (NCI)
|
|
|
Center for Molecular Imaging Research at MGH/HMS
|
5P50CA086355-14
|
$1,449,218
|
$57,969
|
WEISSLEDER, RALPH
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
|
Center for Translational Cancer Nanomedicine
|
5U54CA151881-04
|
$2,343,058
|
$421,750
|
TORCHILIN, VLADIMIR
|
NORTHEASTERN UNIVERSITY
|
|
|
Chronic Lymphocytic Leukemia Research Consortium
|
5P01CA081534-13
|
$3,655,605
|
$731,121
|
KIPPS, THOMAS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
5R44CA124032-05
|
$1,806,651
|
$1,806,651
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
|
Clinical production of viral vectors for cancer gene therapy
|
ZIC BC 010989
|
$670,870
|
$670,870
|
Feldman, Steven
|
CCR (NCI)
|
|
|
Clinical Scholars Biomedical Research Training Program
|
5T32CA009512-27
|
$252,069
|
$50,414
|
KELLY, THOMAS
|
SLOAN-KETTERING INST CAN RES
|
|
|
Clinical Trials of Immunotherapies for Childhood Cancer
|
ZIA BC 011498
|
$552,073
|
$220,829
|
Mackall, Crystal
|
CCR (NCI)
|
|
|
Combination Gene Therapy and Th1/Th2 Therapy
|
ZIA BC 011219
|
$224,566
|
$112,283
|
Fowler, Daniel
|
CCR (NCI)
|
|
|
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE
|
5U01CA151452-04
|
$386,926
|
$386,926
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
|
CONTEMPORARY THERAPEUTICS FOR ANAPLASTIC GLIOMAS
|
5P20CA151129-03
|
$700,000
|
$175,000
|
GILLESPIE, G.
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
|
CpG-siRNA Conjugates to Target Acute Myeloid Leukemia
|
5R01CA155367-03
|
$327,684
|
$327,684
|
KORTYLEWSKI, MARCIN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Cytokine modulated model growth inhibitory mechanisms
|
5R01CA105005-10
|
$246,468
|
$123,234
|
KALVAKOLANU, DHAN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
|
Cytokine Regulation of Normal and Neoplastic Hematopoietic Cell Growth
|
ZIA BC 009264
|
$170,288
|
$3,406
|
Ruscetti, Francis
|
CCR (NCI)
|
|
|
Design of Oncolytic Adenovirus Conjugated with Novel Polymer for Cancer Treatment
|
1R01CA177932-01
|
$309,175
|
$309,175
|
KIM, SUNG WAN
|
UNIVERSITY OF UTAH
|
|
|
Designing Lymph Nodes for Cancer Immunotherapy
|
5R01CA148995-04
|
$315,961
|
$315,961
|
MULE, JAMES
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
|
Determining the mechanistic and therapeutic roles of microRNAs in bladder cancer
|
5R01CA138794-04
|
$245,201
|
$85,820
|
Liang, Gangning
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
Development and evaluation of apoptosis targeted therapies in lung cancer
|
ZIA BC 011049
|
$222,806
|
$222,806
|
Kwong, King
|
CCR (NCI)
|
|
|
Development of Pro-SELEX Aptamer Selection Platform
|
5R44CA150490-03
|
$703,373
|
$351,687
|
DEMPSEY, PAUL
|
CYNVENIO BIOSYSTEMS, INC.
|
|
|
Development of Targeted Therapy for ERK Pathway in Breast Cancer
|
4R00CA139006-03
|
$234,059
|
$234,059
|
Bartholomeusz, Chandra
|
UT MD ANDERSON CANCER CTR
|
|
Total relevant funding to Gene Therapy for this search: $51,944,422
|
